Loading...
•
Nov 30, 2024
Nurix Q4 2024 Earnings Report
Reported financial results for the fourth quarter and fiscal year ended November 30, 2024, and provided a corporate update.
Key Takeaways
Nurix Therapeutics reported Q4 revenue of $13.3 million and a net loss of $58.5 million, or ($0.75) per share. The company's cash, cash equivalents, and marketable securities totaled $609.6 million as of November 30, 2024.
Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL.
Received PRIME designation from the European Medicines Agency for NX-5948 in CLL.
Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom’s Macroglobulinemia.
Announced the appointment of John Northcott as Chief Commercial Officer.
Revenue by Segment
Forward Guidance
Nurix plans to commence a suite of clinical trials designed to support global registration of NX-5948 for the treatment of patients with CLL and to explore its development in inflammatory diseases.
Positive Outlook
- Plans to commence a suite of clinical trials designed to support global registration of NX-5948 for the treatment of patients with CLL.
- Exploring development of NX-5948 in inflammatory diseases.
- Initiating clinical testing of NX-5948 in autoimmune cytopenias in 2025.
- Advancing a pipeline of wholly owned and partnered programs in inflammation and immunology.
- Expecting clinical updates in patients with both CLL and non-Hodgkin’s lymphoma in 2025.
Challenges Ahead
- Uncertainties related to the timing and results of preclinical studies and clinical trials.
- Whether Nurix will be able to fund development activities and achieve development goals.
- Uncertainties related to the timing and receipt of payments from Nurix’s collaboration partners.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...